A carregar...
Publicação
Sacubitril/valsartan: A practical guide
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 451.19 KB | Adobe PDF |
Orientador(es)
Resumo(s)
© 2019 Sociedade Portuguesa de Cardiologia Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormonal balance more than blocking the RAAS alone. The PARADIGM-HF trial validated this new treatment option for patients with HFrEF. Sacubitril/valsartan was also more effective than enalapril in slowing disease progression by decreasing the risk of worsening heart failure requiring hospitalization or emergency admission and the need for intensified therapy, heart failure devices or cardiac transplantation. More than 70% of patients included in PARADIGM-HF were in NYHA class II, and overall, the results indicate that sacubitril/valsartan should be started in the earliest symptomatic stages of the disease. As PARADIGM-HF has excellent robustness for a cardiovascular trial, sacubitril/valsartan has been included as a new treatment option with a strong level of recommendation in the main international guidelines. This expert task force proposes a practical guide to the use of this new drug that has been endorsed by the Working Group on Heart Failure of the Portuguese Society of Cardiology.
Descrição
Funding : Financial support for medical editorial assistance was provided by Novartis Farma --- Produtos Farmacêuticos S.A. The authors had full control of the content and made the final decision on all aspects of this article.
Palavras-chave
Heart failure with reduced ejection fraction PARADIGM-HF Practical guidance Sacubitril/valsartan